| 2022-06-02 |
详情>>
内部人交易：
Duvall Diantha等共交易3笔
|
| 2022-05-05 |
详情>>
业绩披露：
2022年一季报每股收益-0.22美元,归母净利润-1597.8万美元,同比去年增长-33.34%
|
| 2022-04-29 |
复牌提示：
2022-04-28 16:00:37 停牌，复牌日期 2022-04-28 16:35:00
|
| 2022-04-29 |
详情>>
股本变动：
变动后总股本5878.35万股
|
| 2022-03-18 |
详情>>
业绩披露：
2021年年报每股收益-0.48美元,归母净利润-3319.6万美元,同比去年增长24.06%
|
| 2022-03-10 |
财报披露：
美东时间 2022-03-10 盘前发布财报
|
| 2021-10-28 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.29美元,归母净利润-1991.6万美元,同比去年增长30.68%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-07-29 |
详情>>
业绩披露：
2021年中报每股收益-0.24美元,归母净利润-1629.4万美元,同比去年增长32.60%
|
| 2021-04-29 |
股东大会：
将于2021-06-24召开股东大会
会议内容 ▼▲
- 1.To elect Mr. Kenneth Bate and Dr. Ali Behbahani as Class I directors, each for a three-year term;
2.To approve, on an advisory basis, the compensation paid to our named executive officers;
3.To approve an amendment to Genocea’s restated certificate of incorporation to provide that the courts located within the state of Delaware will serve as the exclusive forum for the adjudication of certain legal disputes;
4.To approve an amendment to Genocea’s restated certificate of incorporation to provide for an increase in the total number of shares of common stock that the Company is authorized to issue from 170,000,000 shares to 225,000,000 shares;
5.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2021;
6.To consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-04-29 |
详情>>
业绩披露：
2021年一季报每股收益-0.18美元,归母净利润-1198.3万美元,同比去年增长6.77%
|
| 2021-02-22 |
详情>>
业绩披露：
2020年年报每股收益-0.98美元,归母净利润-4371.4万美元,同比去年增长-12.23%
|
| 2020-10-29 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-0.76美元,归母净利润-2872.9万美元,同比去年增长2.92%
|
| 2020-07-23 |
详情>>
业绩披露：
2020年中报每股收益-0.84美元,归母净利润-2417.4万美元,同比去年增长-9.57%
|
| 2020-04-30 |
详情>>
业绩披露：
2020年一季报每股收益-0.46美元,归母净利润-1285.3万美元,同比去年增长17.43%
|
| 2020-04-20 |
股东大会：
将于2020-06-01召开股东大会
会议内容 ▼▲
- 1.To elect Mr. William Clark, Mr. Ronald Cooper and Dr. George Siber as Class III directors, each for a three-year term;
2.To approve an amendment to the Company’s restated certificate of incorporation to provide for an increase in the total number of shares of common stock that the Company is authorized to issue from 85,000,000 shares to 170,000,000 shares;
3.To approve an amendment to the Genocea Biosciences, Inc. Amended and Restated 2014 Equity Incentive Plan to increase the number of shares of the Company's common stock reserved for issuance thereunder by 2,800,000 shares, to increase the individual non-employee director share limit contained in the plan and to remove the other individual participant limits contained in the plan;
4.To approve, on an advisory basis, the compensation paid to our named executive officers;
5.To approve, on an advisory basis, the frequency of future advisory votes on the compensation paid to our named executive officers;
6.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2020;
7.To consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-02-13 |
详情>>
业绩披露：
2019年年报每股收益-1.89美元,归母净利润-3895万美元,同比去年增长-40.05%
|
| 2019-05-22 |
详情>>
拆分方案：
每8.0000合并分成1.0000股
|
| 2019-03-29 |
股东大会：
将于2019-05-15召开股东大会
会议内容 ▼▲
- 1.To elect Ms. Katrine Bosley and Mr. Michael Higgins as Class II directors, each for a three-year term;
2.To approve an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split (the "Reverse Stock Split Proposal");
3.In the event the shareholders approve the Reverse Stock Split Proposal, to approve an amendment to the Company's restated certificate of incorporation to decrease the total number of shares of common stock that the Company is authorized to issue from 250,000,000 shares to 85,000,000 shares;
4.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2019;
5.To consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2018-04-24 |
股东大会：
将于2018-06-21召开股东大会
会议内容 ▼▲
- 1. To elect Mr. Kenneth Bate, Dr. Ali Behbahani and Dr. Howard Mayer as Class I directors, each for a three-year term;
2. To approve an amendment to the Company’s amended and restated certificate of incorporation to provide for an increase in the total number of shares of common stock that the Company is authorized to issue from 175,000,000 shares to 250,000,000 shares;
3. To approve the Amended and Restated Genocea Biosciences, Inc. 2014 Equity Incentive Plan;
4. To approve an amendment to the Genocea Biosciences, Inc. 2014 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock reserved for issuance thereunder by 2,500,000 shares and to increase the number of shares that may be purchased by a participant on any exercise date by 18,000 shares;
5. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018;
6. To consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-21 |
股东大会：
将于2017-06-13召开股东大会
会议内容 ▼▲
- 1.To elect Mr. William Clark, Mr. Ronald Cooper, and Dr. George Siber as Class III directors, each for a three-year term
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2017;
3.To consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2016-04-21 |
股东大会：
将于2016-06-07召开股东大会
会议内容 ▼▲
- 1. To elect Ms. Katrine Bosley, Mr. Michael Higgins, and Dr. Stephen Hoffman as Class II directors, each for a three-year term;
2. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2016;
3. To consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2015-04-16 |
股东大会：
将于2015-06-04召开股东大会
会议内容 ▼▲
- 1. To elect Mr. Kenneth Bate and Dr. Kevin Bitterman as Class I directors, each for a three-year term;
2. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2015;
3. To consider and act upon any other matters that properly come before the Annual Meeting or any adjournment or postponement thereof.
|